Klaus A. Dugi

5.6k total citations
72 papers, 4.4k citations indexed

About

Klaus A. Dugi is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Klaus A. Dugi has authored 72 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Endocrinology, Diabetes and Metabolism, 32 papers in Surgery and 23 papers in Molecular Biology. Recurrent topics in Klaus A. Dugi's work include Diabetes Treatment and Management (25 papers), Pancreatic function and diabetes (19 papers) and Lipid metabolism and disorders (13 papers). Klaus A. Dugi is often cited by papers focused on Diabetes Treatment and Management (25 papers), Pancreatic function and diabetes (19 papers) and Lipid metabolism and disorders (13 papers). Klaus A. Dugi collaborates with scholars based in Germany, United States and United Kingdom. Klaus A. Dugi's co-authors include Hans J. Woerle, Silvia Santamarina-Fojo, Arne Ring, Maximilian von Eynatten, Eva U. Graefe-Mody, Peter P. Nawroth, Julio Rosenstock, H. Bryan Brewer, Hans‐Juergen Woerle and Jochen G. Schneider and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Circulation.

In The Last Decade

Klaus A. Dugi

71 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Klaus A. Dugi Germany	39	2.9k	1.6k	1.4k	806	741	72	4.4k
Mark Kipnes United States	31	2.9k 1.0×	1.3k 0.9×	1.2k 0.9×	717 0.9×	322 0.4×	57	4.3k
Marian C. Cheung United States	38	3.2k 1.1×	3.0k 1.9×	1.3k 0.9×	301 0.4×	930 1.3×	74	5.9k
Timo Rieg United States	38	2.1k 0.7×	1.4k 0.9×	2.5k 1.7×	497 0.6×	408 0.6×	86	5.2k
Kohei Kaku Japan	47	4.7k 1.6×	2.7k 1.7×	3.4k 2.4×	498 0.6×	462 0.6×	398	7.7k
Yan Gong United States	39	1.4k 0.5×	695 0.4×	1.3k 0.9×	593 0.7×	1.8k 2.4×	200	4.9k
S. Dejager France	37	4.4k 1.5×	2.6k 1.7×	1.7k 1.2×	905 1.1×	449 0.6×	95	6.0k
Sheldon Chen United States	37	1.1k 0.4×	787 0.5×	2.5k 1.8×	531 0.7×	895 1.2×	63	7.0k
Linda Morrow United States	29	1.8k 0.6×	1.1k 0.7×	1.1k 0.8×	397 0.5×	412 0.6×	81	3.6k
Shin‐ichi Araki Japan	44	1.6k 0.5×	887 0.6×	1.9k 1.3×	255 0.3×	801 1.1×	139	6.5k
Francesco Purrello Italy	38	2.5k 0.9×	2.2k 1.4×	1.6k 1.1×	198 0.2×	528 0.7×	186	5.4k

Countries citing papers authored by Klaus A. Dugi

Since Specialization

Citations

This map shows the geographic impact of Klaus A. Dugi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus A. Dugi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus A. Dugi more than expected).

Fields of papers citing papers by Klaus A. Dugi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus A. Dugi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus A. Dugi. The network helps show where Klaus A. Dugi may publish in the future.

Co-authorship network of co-authors of Klaus A. Dugi

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus A. Dugi. A scholar is included among the top collaborators of Klaus A. Dugi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus A. Dugi. Klaus A. Dugi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hildebrandt, Wulf, Roland Sauer, Gabriel A. Bonaterra, et al.. (2015). Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status. American Journal of Clinical Nutrition. 102(5). 1014–1024. 24 indexed citations

Zimdahl, Heike, Carina Ittrich, Ulrike Graefe‐Mody, et al.. (2014). Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia. 57(9). 1869–1875. 46 indexed citations

Seman, Leo, Sreeraj Macha, Gerhard Nehmiz, et al.. (2013). Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Clinical Pharmacology in Drug Development. 2(2). 152–161. 111 indexed citations

Kempf, Kerstin, et al.. (2013). The Epidemiological Boehringer Ingelheim Employee Study—Part I: Impact of Overweight and Obesity on Cardiometabolic Risk. Journal of Obesity. 2013. 1–10. 12 indexed citations

Sarashina, Akiko, Kazuki Koiwai, Leo Seman, et al.. (2012). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects. Drug Metabolism and Pharmacokinetics. 28(3). 213–219. 73 indexed citations

Wild, Philipp S., Tanja Zeller, Manfred E. Beutel, et al.. (2012). Die Gutenberg Gesundheitsstudie. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 55(6-7). 824–830. 191 indexed citations

Kawamori, Ryuzo, Nobuya Inagaki, Eiichi Araki, et al.. (2011). Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study. Diabetes Obesity and Metabolism. 14(4). 348–357. 101 indexed citations

Prato, Stefano Del, Anthony Barnett, Holger Huisman, et al.. (2010). Effect of linagliptin monotherapy on glycaemic control and markers of β ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obesity and Metabolism. 13(3). 258–267. 259 indexed citations

Graefe‐Mody, Ulrike, et al.. (2010). Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. International Journal of Clinical Pharmacology and Therapeutics. 48(6). 367–374. 35 indexed citations

10.

Morcos, Michael, Andrea Schlotterer, G Kukudov, et al.. (2008). Rosiglitazone Reduces Angiotensin II and Advanced Glycation End Product-dependent Sustained Nuclear Factor-κB Activation in Cultured Human Proximal Tubular Epithelial Cells. Hormone and Metabolic Research. 40(11). 752–759. 25 indexed citations

11.

Eynatten, Maximilian von, Philipp M. Lepper, D. Liu, et al.. (2007). Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 50(9). 1930–1937. 146 indexed citations

12.

Eynatten, Maximilian von, Per M. Humpert, Philipp M. Lepper, et al.. (2007). High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis. 199(1). 123–128. 68 indexed citations

13.

Eynatten, Maximilian von, Jochen G. Schneider, Per M. Humpert, et al.. (2004). Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia. Diabetes Care. 27(12). 2925–2929. 116 indexed citations

14.

Hildebrandt, Wulf, A. Hamann, Holger Krakowski‐Roosen, et al.. (2004). Effect of thiol antioxidant on body fat and insulin reactivity. Journal of Molecular Medicine. 82(5). 336–344. 41 indexed citations

15.

Schneider, Jochen G., et al.. (2002). Siblings with hepatosplenomegaly and lipoprotein lipase deficiency. The Lancet. 360(9340). 1150–1150. 3 indexed citations

16.

Dugi, Klaus A., et al.. (2002). Activity and concentration of lipoprotein lipase in post-heparin plasma and the extent of coronary artery disease. Atherosclerosis. 163(1). 127–134. 11 indexed citations

17.

McConnell, Daniel & Klaus A. Dugi. (2000). The Endothelium and Lipoproteins: Insights from Recent Cell Biology and Animal Studies. Seminars in Thrombosis and Hemostasis. 26(5). 521–528. 38 indexed citations

18.

Malle, Ernst, Karl Pfeiffer, Klaus A. Dugi, et al.. (1996). Polymorphisms of apolipoproteins A-IV and E in a Turkish population living in Germany. Human Genetics. 98(3). 285–290. 12 indexed citations

19.

Dugi, Klaus A., et al.. (1994). Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Current Opinion in Lipidology. 5(2). 117–125. 102 indexed citations

20.

Ehlenz, K., H. Schneider, Klaus A. Dugi, et al.. (1991). WELCHE ROLLE SPIELT DAS RENIN-ANGIOTENSIN-ALDOSTERON-SYSTEM (RAAS) IN DER PATHOGENESE DER HYPERTONIE BEIM OBSTRUKTIVEN SCHLAFAPNOE-SYNDROM (OSAS)?. 20(10). 548–550. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact